Novo Nordisk Shares Fall as Wegovy Pill Disappoints in Trials
Novo Nordisk stock dropped after its oral Wegovy formulation missed expectations, overshadowing an improved annual outlook from the Danish drugmaker.
Novo Nordisk shares slid again Thursday as investors reacted to a surprise clinical disappointment tied to an oral version of its blockbuster weight-loss drug Wegovy, dealing a fresh blow to the Danish pharmaceutical giant after months of stock pressure.
The pill formulation of Wegovy — seen as a critical next step in expanding the obesity drug market beyond injections — failed to meet expectations, a setback that analysts and investors had not fully priced in. The miss raises questions about how quickly Novo Nordisk can broaden its obesity franchise into a more patient-friendly, needle-free format that could potentially unlock a far larger customer base.
Read more S&P 500's Most Active Stocks to Watch This Tuesday →
The disappointment came even as the company offered a brighter financial picture for the full year, revising its annual outlook upward. The improved guidance, however, was not enough to offset the market's concern over the pill's stumble, underscoring how heavily Novo Nordisk's valuation has become tied to its pipeline ambitions rather than near-term earnings alone.
Novo Nordisk has faced intensifying competition from rival Eli Lilly, whose own obesity and diabetes portfolio has drawn significant investor enthusiasm. A setback on the oral Wegovy front could further shift momentum toward competitors at a time when the weight-loss drug race is accelerating across the industry.
The stock's renewed slide reflects broader anxiety about whether Novo Nordisk can maintain its dominant position in the GLP-1 drug market as the landscape grows more crowded and the bar for innovation climbs higher. Continue reading at MarketWatch.com
